Valneva Announces Plans for Extraordinary General Meeting to Prepare for Potential US IPO
10 Novembre 2020 - 5:45PM
Saint-Herblain (France), November 10, 2020 –
Valneva SE (“Valneva” or “the Company”), a specialty vaccine
company, today announced that it will convene an Extraordinary
General Meeting (EGM) to be held on December 22, 2020.
From November 16, 2020, the preparatory
documents and information for the Extraordinary General Meeting
will be available and posted on the Company’s website, in
accordance with applicable French laws and regulations.
Valneva is calling the EGM in order to obtain
the necessary authorizations to allow the Company to prepare for a
potential listing and public offering of American Depositary Shares
(each representing a number of the Company’s ordinary shares) on
Nasdaq in 2021 (the “Offering”), subject to market and other
conditions, consistent with the Company’s previously communicated
strategic plans. The timing, number of securities to be
offered and their price have not yet been determined. The Company
plans to submit a confidential draft registration statement to the
Securities and Exchange Commission (the “SEC”) in early 2021, and
the proposed Offering is expected to commence after the SEC
completes its review processes, subject to market and other
conditions. Shareholders and potential investors should note that
the proposed Offering may or may not proceed.
This press release is being made pursuant to,
and in accordance with, Rule 135 under the Securities Act of 1933,
as amended (the “Securities Act”). This press release does not
constitute an offer to sell or the solicitation of an offer to buy
securities, and shall not constitute an offer, solicitation or sale
in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of that jurisdiction. Any offers, solicitations or
offers to buy, or any sales of securities will be made in
accordance with the registration requirements of the Securities
Act.
About Valneva SEValneva is a
specialty vaccine company focused on prevention against diseases
with major unmet needs. The Company has several vaccines in
development including unique vaccines against Lyme disease,
COVID-19 and chikungunya. Valneva’s portfolio includes two
commercial vaccines for travelers: IXIARO®/JESPECT® indicated for
the prevention of Japanese encephalitis and DUKORAL® indicated for
the prevention of cholera and, in some countries, prevention of
diarrhea caused by ETEC.
Valneva
Investor and Media ContactsLaetitia
Bachelot-FontaineDirector Investor Relations & Corporate
CommunicationsM +33 (0)6 4516
7099investors@valneva.com |
Teresa
PinzolitsCorporate Communications SpecialistT +43 (0)1 20620
1116communications@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the potential Offering, the progress,
timing and completion of research, development and clinical trials
for product candidates, the ability to manufacture, market,
commercialize and achieve market acceptance for product candidates,
the ability to protect intellectual property and operate the
business without infringing on the intellectual property rights of
others, estimates for future performance and estimates regarding
anticipated operating losses, future revenues, capital requirements
and needs for additional financing. In addition, even if the actual
results or development of Valneva are consistent with the
forward-looking statements contained in this press release, those
results or developments of Valneva may not be indicative of their
in the future. In some cases, you can identify forward-looking
statements by words such as "could," "should," "may," "expects,"
"anticipates," "believes," "intends," "estimates," "aims,"
"targets," or similar words. These forward-looking statements are
based largely on the current expectations of Valneva as of the date
of this press release and are subject to a number of known and
unknown risks and uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from any future results, performance or achievement
expressed or implied by these forward-looking statements. In
particular, the expectations of Valneva could be affected by, among
other things, uncertainties involved in the development and
manufacture of vaccines, unexpected clinical trial results,
unexpected regulatory actions or delays, competition in general,
currency fluctuations, the impact of the global and European credit
crisis, and the ability to obtain or maintain patent or other
proprietary intellectual property protection. In light of these
risks and uncertainties, there can be no assurance that the
forward-looking statements made in this press release will in fact
be realized. Valneva is providing the information in these
materials as of this press release, and disclaim any intention or
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise.
Please refer to the Universal Registration
Document filed with the Autorité des Marchés Financiers on March
30, 2020 under n° D.20-0217 for additional information in relation
to such factors, risks and uncertainties.
- 2020_11_10_ VLA_EGM_IPO_PR_EN_Final